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HbA1c is a standard clinical assessment of glycemia and the basis of most data relating glycemic control to complications. While
daily blood glucose testing gives a picture of day-to-day ﬂuctuations, the HbA1c test oﬀers an overview of how well glucose has
been controlled over the past 4 months. I devised an innovative mathematical model to describe novel equations governing HbA1c
which enables analysis of HbA1c behavior and provides emerging new concepts in assessment of diabetes management. Linear
relationship of HbA1c and mean plasma glucose along with the kinetic analysis of HbA1c formation has been used as the basic
suppositions to construct this model. The main application of this devised model is prediction of mean plasma glucose at any
desired point in time after a change in therapy and with great certainty. This model also appraises the pattern of HbA1c changes
over time and provides a unique opportunity to address common mistakes and misconceptions in routine application of HbA1c
that could have potentially important implications on diabetes control.
1.Introduction
Maintenance of blood glucose levels as close as possible to
the nondiabetic range over time is an important goal in the
current management of patients with diabetes. Assessment
of a patient’s diabetes management can be accomplished
by directly analyzing the pattern of multiple blood glucose
samples drawn over time [1]. However, a high degree of
cooperation is required on the part of the patient to collect
as u ﬃcient number of blood glucose samples that adequately
represent typical diurnal glucose patterns. Once collected,
statistical analysis is then necessary to assess the central
tendency and variability of glucose levels. As an alternative,
a patient’s HbA1c level can be easily and conveniently
determined from a single blood sample.
A large number of studies have shown that HbA1c is
strongly associated with the preceding mean plasma glucose
(MPG) over previous weeks and months [2–5]. Based on the
statistical relation of HbA1c and MPG, HbA1c is widely used
as a clinical estimation of MPG, and it has been proposed
as a diagnostic criterion for diabetes, as well [6]. HbA1c has,
therefore, become a standard assessment of glycemia [7]a n d
a standard part of diabetes management.
One of the most important limitations of HbA1c is
that it is not applicable in short intervals. Erythrocyte life
span in normal conditions averages ∼120 days, and the
glycation of hemoglobin (Hb) is a continuous, nonenzy-
matic, relatively slow and nearly irreversible process [8]
that means change in eﬀects of previous glycation on Hb
takes several weeks to months to occur. To permit a much
clearer assessing of diabetes management, it is generally
recommended that the HbA1c assay be used every 2-3
months. Ideally, if measured each 120 days (4 months)
it gives a precise estimation of MPG over preceding 4
months, reliably comparable to previous HbA1c value. If
measurement is taken earlier than erythrocyte life span
intervals (4 months), because of existing previously gly-
cated Hbs which have not reached end of their lives,
the estimated MPG would be aﬀected by previous plasma
glucose levels. This would be an important issue, and if
measuredfollowingasigniﬁcantvariationsinplasmaglucose
during changes in patient’s diabetes control or medication,
then it would end to a remarkable error in estimation of
MPG.
I devised an innovative mathematical model to describe
novel equations governing HbA1c which enables analysis of2 International Journal of Endocrinology
HbA1c behavior and provides emerging new concepts in
assessment of diabetes management.
2. SuppositionsandTheory
Quarterly HbA1c and corresponding seven-point capillary
blood glucose proﬁles obtained in the DCCT have been
analyzedtodeﬁnetherelationshipbetweenHbA1c andMPG.
HbA1c is linearly related to MPG based on linear regression
analysis weighted by the number of observations per subject
(Figure 1), producing a relationship of [9]
MPG

mg/dl

= 35.6 ×HbA1c −77.3. (1)
or
HbA1c =
1
35.6
MPG+2.17. (2)
MPG at increasing levels of HbA1c is shown in Table 1
based on DCCT data correlating HbA1c with MPG using 7-
point blood glucose proﬁles along with ADAG data using
continuous glucose monitoring systems [5, 9].
The kinetic analysis of HbA1c formation depicted in
Figure 2showsthelinearrelationshipbetweenHbA1c forma-
tion rate and time, with the slope proportional to the MPG
[10].Thehigherthebloodglucoseis,thefasterHbA1c willbe
formed,resultinginhigherHbA1c levels.Italsodemonstrates
the distribution of HbA1c amount in erythrocytes with
diﬀerent ages. For instance, it is elicited from the curve
MPG = 137, that the HbA1c rate in newly born RBCs is
0%, and in RBCs with 60 and 120 days old, 6 and 12%,
respectively.
It can be corroborated that the mean HbA1c in a
collectionoferythrocyteswithdiﬀerentagesandHbA1c rates
is the median point or arithmetic mean of the upper and
lower limits of the curve. Erythrocyte life span in normal
conditions is about 120 days and the level of HbA1c at any
point in time is contributed to by allcirculating erythrocytes,
from the oldest (120 days old) to the youngest. Since the rate
of RBC formation is equal to its degradation, the percentage
of RBC count in a single day is 1/120 of total RBC mass.
Hence, 1/120 of RBC collection are one day old, 1/120 are
two days old, and likewise 1/120 are 120 days old. The mean
value of HbA1c in a collection of RBCs with diﬀerent ages
can be calculated by averaging of HbA1c rate in each RBC as
follows:
MeanHbA1c =
120
1 εn ×(1/120)RBCmass
RBCmass
, (3)
whereεn isHbA1c rateinRBCswithndaysoldandRBCmass
is total number of RBCs in the body. Since glycation of Hb
according to Figure 2 follows a linear pattern, it is expected
that
ε2 = 2ε1, ε3 = 3ε1,..., ε120 = 120ε1. (4)
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Figure 1: Linear regression analysis of MPG versus HbA1c:t h e
Pearson correlation coeﬃcient (r) is 0.82; MPG (mg/dl) = 35.6 ×
HbA1c −77.3.
Table 1: Regression-estimated MPG at diﬀerent HbA1c levels based
on DCCT and Nathan’s data.
HbA1c
(%)
DCCT-estimated MPG ADAG-stimated MPG
mmol/l mg/dl mmol/l mg/dl
5 5.6 101 5.4 97
6 7.6 137 7.0 126
7 9.6 172 8.6 154
8 11.5 208 10.2 183
9 13.5 244 11.8 212
10 15.5 279 13.4 240
11 17.5 315 14.9 269
12 19.5 350 16.5 298
Hence,
HbA1c =
(1/120)RBCmass ×(ε1 +ε120) ×(120/2)
RBCmass
=
(ε1 +ε120)
2
.
(5)
Accordingly,themeanvalueofHbA1c inacollectionofRBCs
would be the arithmetic mean of upper and lower limits of
the curve.
The mathematical relationship between data leading to
the curves depicted in Figure 2 can be correlated by the
following formula:
HbA1c =
MPG/35.6+2 .17
2
m, (6)
where MPG contributes the mean plasma glucose in which
Hb glycation is progressing and m is the variation of time in
month.
We will now map this model into mathematical expres-
sions and start with an example.
Example 1. Assume that you have visited a diabetic patient
with HbA1c = 9% and MPG = 244mg/dl and after
adjusting the medications, patient’s MPG has fallen to the
curve MPG = 137 as visualized by graphic presentationInternational Journal of Endocrinology 3
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Figure 2:RateofformationofHbA1c simulatedfromresultsofpro-
longed incubation of HbA0 with glucose in diﬀerent concentration.
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Figure 3:Plottedgraphdemonstratingprocessofeventshappening
in the hypothetical Example 1.
in Figure 3. After one month you are interested in calculating
the HbA1c which is the mixture of previously and newly
glycated Hbs and is estimated to be in range of 6% to 9%.
As described in Figure 3, after passing one month of
changes in MPG, the erythrocytes with 3 to 4 months old
will reach the end of their lives and destroy themselves. The
remaining RBCs have HbA1c ranging from 0 to 13.5%. This
upper extreme can be calculated as
ΦUpper =
MPG1/35.6+2 .17
2
(4 −m) =
Hb1
2
(4 − m)
= 13.5%.
(7)
As described before (by (5)) the mean value of HbA1c in
this group of RBCs is arithmetic mean of upper and lower
extremes of the curve, that is
Φmean =
ΦUpper
2
=
MPG1/35.6+2 .17
4
(4 −m)
=
Hb1
4
(4 −m) = 6.75%.
(8)
Over the past one month, these previously glycated RBCs
undergo new glycation on the curve MPG = 137 to
convey the prior mean HbA1c to a newly higher point. This
displacement of mean HbA1c point on the second curve over
m months can be written as
ΔΦmean =
MPGx/35.6+2 .17
2
m =
Hbx
2
m = 3%. (9)
The sum of contributions (8)a n d( 9) represents the cumula-
tive mean HbA1c in this group of RBCs with former and later
glycation on two diﬀerent curves.
Φ1 =
MPG1/35.6+2 .17
4
(4 −m)+
MPGx/35.6+2 .17
2
m
=
Hb1
4
(4 − m)+
Hbx
2
m = 9.75%.
(10)
Furthermore, during the past one month, second group of
RBCs have been newly formed and undergone glycation on
the new curve (MPG = 137) with mean HbA1c of
Φ2 =
MPGx/35.6+2 .17
4
m =
Hbx
4
m = 1.5%. (11)
Following all above steps, we can ﬁnd the ﬁnal desired
HbA1c by averaging equations Φ1 and Φ2 considering their
coeﬃcients according to available RBCs in each group (3:1,
three months versus one month).
Hbmix =
Φ2 × m+Φ1 ×(4 −m)
4
,
Hbmix =
((MPGx/35.6+2 .17)/4)m2
4
+

MPG1
35.6 +2.17
4 (4 −m)+
MPGx
35.6 +2.17
2 m

4
×
(4 −m)
4
,
Hbmix =
(Hbx/4)m2 +((Hb1/4)(4 −m)+(Hbx/2)m)
4
×
(4 −m)
4
.
(12)
And rearranging gives
Hbmix =
MPGx

8m −m2
+MPG 1

m2 −8m +16

+ 1236
570
.
(13)
or
Hbmix =
Hbx

8m −m2
+Hb 1

m2 −8m +16

16
= 7.6875%.
(14)
Therefore, the estimated HbA1c after one month would be
7.6875%.Althoughthisistheanswertoourinitialriddle,this
value (Hbmix) is a simply measurable variable by laboratory
assays. In fact, our unknown desirable variable in this setting
would be MPGx and Hbx representative of the second curve
in which glycation occurs over recent months. And this is4 International Journal of Endocrinology
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Figure 4: Changes in HbA1c versus time for the patient presented
in Example 2.
the ﬁnding that was one of the most important limitations
of HbA1c,s o m em i n u t e sa g o .
Access to the equations governing HbA1c by this compre-
hensive analysis could have potentially valuable implications
on diabetes control. No matter how frequently done, mea-
surement of HbA1c can lead to the desirable mean plasma
glucose over previous m months and makes all doubts about
time wasting over patient’s observations, even. Finally, for
practical aspects of this model in clinical setting,
MPGx =
570 ×Hbmix −MPG1 ×

m2 −8m +1 6

− 1236
(8m −m2)
.
(15)
or
Hbx =
16 ×Hbmix −Hb1 ×

m2 − 8m+1 6

(8m −m2)
, (16)
where
(i) Hb1: initially measured HbA1c,
(ii) Hbmix:m e a s u r e dH b A 1c after m months,
(iii) Hbx:H b A 1c corresponding to the curve on which the
patient has moved during previous m months,
(iv) m: time interval between measuredHb1 and Hbmix in
month.
It is of note that, the ﬁnal equation (16) is independent
of presumed equations correlating HbA1c with MPG such
as DCCT data ((1)a n d( 2)) or other data such as Nathan’s
et al. [5]. The calculated Hbx has a capability to be converted
to the corresponding MPG using any of mentioned HbA1c-
MPG relationships (Table 1).
Table 2: Percentage of changes in HbA1c during time intervals.
Month First Second Third Forth
During 44% 31% 17% 8%
Total changes at the end of 44% 75% 92% 100%
Example 2. Assume a diabetic patient with Hb1 = 12% and
MPG1 = 350 to whom changing in therapeutic regimens is
applied. After two weeks, the rechecked HbA1c is Hbmix =
11%. According to (16), the mean plasma glucose in recent
two weeks can be calculated as
Hbx =
16 ×11 −12 ×(0.25 − 4+16)
(4 −0.25)
= 6.93%. (17)
Hbx = 6.93% represents that the patient is shifted to
and moving on the curve MPG = 170 (see (1)) showing
a signiﬁcant improvement in patient’s diabetic control.
Otherwise, the measured Hbmix = 11% corresponds to
the MPG = 315 with a remarkable error and deviation
from reality due to a mixture of former and later glycated
Hemoglobins.
It is of note that, variation in glycation rates between
individuals and also diﬀerence in RBC life span especially
in hemoglobinopathies are not factored in this model to
attenuate intricacy of equations.
Another application of this derived mathematical model
is describing the changes in HbA1c with time. For the patient
presented in Example 2,( 14) takes the form of
Hbmix =
6.93 ×

8m −m2
+1 2×

m2 − 8m+1 6

16
. (18)
and can be plotted as in Figure 4.
Percentage of changes in HbA1c during the time intervals
can be expressed as
ΔHbA1c =
Hb1 −Hbmix(time −related)
Hb1 −Hbx
× 100. (19)
and is presented in Table 2.
The calculated changes of HbA1c over time derived
from devised mathematical model are in full quantitative
agreement with previous clinical studies [11–13] showing
thatplasmaglucoselevelsinthepreceding30dayscontribute
∼50% to the ﬁnal results, and PG levels from 90–120 days
earlier contribute only ∼10%.
As brieﬂy described, without applying the presented
equations, early measurement of HbA1c will end to a crude
and erroneous estimation of patient’s MPG. How frequently
shoulditbecheckedisagreatcontroversyamongauthorities,
but the general trend and recommendation vary from 2 to 3
months.
Additional application of our mathematical model is
calculation of emerged error at any desired time intervals,
deﬁned as deviation of the crude estimation of MPG derivedInternational Journal of Endocrinology 5
Table 3: MPG1 versus Hbmix showing estimated error of measured HbA1c for detection of patient’s MPG in 2-month intervals. Out of range
data are ignored.
Error2 101 137 172 208 244 279 315 350 385 420
50 −12.8 −29.5 −52.9
68 . 3 2 0 −8.83 −20.2 −34.3 −51.6
7 12.37 6.723 0 −6.86 −15.4 −25.1 −36.9 −50.8
8 14.84 10.48 5.785 0 −5.61 −12.2 −19.9 −28.5 −38.4 −49.9
9 16.51 12.96 9.203 4.987 0 −4.59 −10.2 −16.3 −23.1 −30.8
10 17.71 14.72 11.59 8.129 4.385 0 −3.97 −8.65 −13.8 −19.4
11 18.61 16.03 13.35 10.42 7.281 4.01 0 −3.39 −7.47 −11.9
12 19.32 17.04 14.71 12.16 9.465 6.676 3.622 0 −2.93 −6.55
13 19.88 17.85 15.78 13.54 11.17 8.742 6.102 3.383 0 −2.55
14 20.35 18.52 16.65 14.65 12.54 10.39 8.067 5.689 3.184 0
Table 4: MPG1 versus Hbmix showing estimated error of measured HbA1c for detection of patient’s MPG in 3-month intervals.
Error3 101 137 172 208 244 279 315 350 385 420
50 −2.27 −4.76 −7.44 −10.3 −13.2 −16.3 −19.5 −22.9 −26.5
6 1.846 0 −1.62 −3.47 −5.39 −7.33 −9.4 −11.5 −13.7 −15.9
7 2.806 1.469 0 −1.28 −2.73 −4.19 −5.73 −7.27 −8.85 −10.5
8 3.427 2.336 1.25 0 −1.06 −2.22 −3.45 −4.66 −5.91 −7.19
9 3.861 2.939 2.026 1.069 0 −0.88 −1.89 −2.9 −3.92 −4.97
10 4.182 3.384 2.596 1.772 0.933 0 −0.76 −1.62 −2.49 −3.38
11 4.428 3.725 3.032 2.308 1.574 0.849 0 −0.65 −1.41 −2.18
12 4.624 3.996 3.377 2.732 2.078 1.434 0.763 0 −0.57 −1.25
13 4.783 4.215 3.656 3.074 2.485 1.906 1.303 0.71 0 −0.5
14 4.914 4.396 3.886 3.357 2.821 2.295 1.747 1.209 0.665 0
via Hbmix, from real MPG calculated by devised equations
error =
MPGreal −MPGcrude
MPGreal
×100. (20)
or
error = 1 −
(35.6 ×Hbmix −77.3) 
570×Hbmix−MPG1×(m2−8m+16)−1236
(8m−m2)
 × 100. (21)
To make the presented 3-variable equation more applicable,
it can be used at deﬁnite points of time with diﬀerent values
of MPG1 and laboratory measured Hbmix. As an instance,
errorestimationofmeasuredHbA1c fordetectionofpatient’s
meanplasmaglucosein2and3monthsintervalsisexpressed
in Tables 3 and 4 according to diﬀerent values of MPG1 and
Hbmix.
As presented in Tables 3 and 4, estimated error emerged
in diﬀerent values of MPG1 and Hbmix ranges from −50%
to +20% for 2-month interval and −26% to +5% for
3-month interval. Negative and positive errors contribute
to overestimation and underestimation of patient’s MPG,
respectively. The higher the diﬀerence between Hb1 and
Hbmix is, the bigger the error emerged from crude estimation
of patient’s MPG via laboratory measured Hbmix.
3. Discussion
Hemoglobin is continuously glycated during the 120-day
life span of erythrocyte such that the cumulative amount of
HbA1c in an erythrocyte is directly proportional to the time-
averaged concentration of glucose within the erythrocyte
[8, 10, 14, 15]. Glycated hemoglobins provide an index of
the patient’s average blood glucose concentration over a
long time period. This index is not aﬀected by short-term
ﬂuctuations in blood sugar (hour to hour) and hence gives
a relatively precise reﬂection of the state of blood glucose
control in diabetes.
To introduce novel applications and new concepts about
HbA1c, an innovative mathematical simulation was analyt-
ically modeled to describe the HbA1c behavior and process
of events. The basic suppositions are cited from available
equations expressed in Figures 1 and 2 [9, 10]. The devised
model is used to predict the mean plasma glucose at any
desired point in time with great certainty. By using derived
formulas, it does not take 120 days to detect a clinically
meaningful and reliable value for HbA1c and MPG over
preceding months.
In addition to the presented application, I speciﬁcally
was interested in assessing the pattern of HbA1c changes
over time and calculation of emerged error during crude
estimation of MPG from Hbmix. As described in Table 26 International Journal of Endocrinology
and Figure 4,c h a n g ei nH b A 1c shows a prompt fall upon
institution of rigorous diabetic control. This ﬁnding can be
readily explained by decay of older erythrocytes with highest
ratesofglycatedHb,asdemonstratedinFigure 3.Thismodel
refutes the explanation that recent PG levels (i.e., 3-4 weeks
earlier) contribute considerably more to the level of HbA1c
thandolongpastPGlevels(i.e.,3-4monthsearlier)[11–13].
Accordingtocalculatederrorfor2-and3-monthinterval
and its explained logic, without employment of the devised
model, HbA1c should be used with caution as a surrogate
measure of MPG because it may signiﬁcantly under or
overestimate patient’s MPG.
The tests currently in use for diagnosis are the fasting
plasma glucose test and the less common oral glucose
tolerance test. However, these tests can be inaccurate if a
person has eaten recently or is sick. Advantages of the HbA1c
test are that it can be given at any time and, because it reﬂects
blood glucose levels over a longer period, it is not unduly
inﬂuenced by events on the day of the test. This devised
model also makes HbA1c more beﬁtting and useful for being
a main part of guidelines on using the HbA1c test as a
diagnostic tool for diabetes. However, a consensus statement
isnecessarybecauserightnow thereisnoagreementonwhat
HbA1c level would constitute a diagnosis of diabetes.
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